ReGenTree
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
116 Village Blvd Ste 200, Princeton, New...Phone Number
(609) 734-4328Website
www.regentreellc.comRevenue
$10.1 MillionIndustry
About ReGenTree
ReGenTree, LLC is a Princeton, New Jersey-based pharmaceutical joint venture between RegeneRx Biopharmaceuticals and GtreeBNT Co., Ltd. formed to develop the therapeutic peptide RGN-259 for ophthalmic conditions in the United States and Canada. The company has sponsored multiple Phase 3 clinical trials for dry eye syndrome, including the ARISE series, as well as studies for neurotrophic keratopathy, a rare orphan-designated corneal disease. ReGenTree aims to become a leading pharmaceutical company specializing in ophthalmology through its novel, preservative-free eye drop formulations.Explore more
SIC Code 28,283NAICS Code 32,325Show more
ReGenTree Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to ReGenTree
Compare insights from companies similar to ReGenTree, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
ReGenTree Tech Stack
A closer look at the technologies used by ReGenTree
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ReGenTree
Sign Up For FreeTo access detailed company insights
ReGenTree, LLC is a Princeton, New Jersey-based pharmaceutical joint venture between RegeneRx Biopharmaceuticals and GtreeBNT Co., Ltd. formed to develop the therapeutic peptide RGN-259 for ophthalmic conditions in the United States and Canada. The company has sponsored multiple Phase 3 clinical trials for dry eye syndrome, including the ARISE seri... Read More
